Jopamiro (Iopamidol)

Iopamidol works by providing a high concentration of iodine atoms that absorb X‑ray photons. When injected into the vascular system, the iodine attenuates the X‑ray beam, creating a contrast between blood‑filled structures and surrounding tissues. This enhanced radiodensity enables detailed imaging of vessels, organs, and urinary pathways during radiographic examinations.

The dose of Jopamiro is determined by the prescribing physician based on the specific imaging study, patient weight, renal function, and the required iodine load. Healthcare professionals calculate the appropriate volume and concentration for each procedure, and the medication is administered under controlled clinical conditions.

Safety of iopamidol in pregnancy and lactation has not been definitively established. It is generally classified as a category where benefits must outweigh potential risks. Clinicians should evaluate the necessity of contrast‑enhanced imaging in pregnant or nursing patients and consider alternative modalities when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Jopamiro. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Jopamiro (iopamidol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. Compared with other low‑osmolality agents such as iohexol or iopromide, iopamidol provides similar image quality while potentially reducing the incidence of discomfort and adverse reactions, though individual patient factors guide selection.

Jopamiro should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture, and freezing. Before use, inspect the solution for particulate matter or discoloration, and allow it to reach room temperature if stored in a cooler environment.

Jopamiro is supplied as a sterile injectable solution for intravenous or intra‑arterial administration. The medication is injected by a qualified healthcare professional using aseptic technique, typically through a peripheral or central venous line, or directly into an arterial catheter, depending on the imaging procedure being performed.

The most serious risks include severe allergic reactions such as anaphylaxis, contrast‑induced nephropathy leading to acute kidney injury, thyroid dysfunction from iodine load, and rare cardiac events like arrhythmias. Prompt recognition and management of these reactions are essential, and patients with known risk factors should be closely monitored.

Jopamiro is contraindicated in patients with a known hypersensitivity to iopamidol or any iodinated contrast media, those with uncontrolled severe asthma, and individuals with unstable renal function where the risk of contrast‑induced nephropathy outweighs diagnostic benefit. Clinicians should also exercise caution in patients with thyroid disorders, heart failure, or a history of severe allergic reactions.